Two UC San Diego Researchers to Lead Alzheimer’s Disease Cooperative Study.
By Paul Aisen, M.D. Director, Alzheimer’s Disease Cooperative Study Professor of Neurosciences, University of California San Diego There has been much discussion in the news lately as to whether the amyloid hypothesis is the correct path for research. The amyloid hypothesis is supported by a huge body of evidence, but to my thinking the most…
When a neuron gets blocked, the delicate harmony that allows the brain to operate seamlessly deteriorates. One result: diseases like Alzheimer’s. Understanding such blockages and how “traffic” should flow normally in healthy brain cells could offer hope to people with neurodegenerative diseases.
Toward that end, a research team led by University at Buffalo biologist Shermali Gunawardena, PhD, has shown that the protein presenilin plays an important role in controlling neuronal traffic on microtubule highways, a novel function that previously was unknown.
“Our results demonstrate that ApoE affects tau pathogenesis, neuroinflammation, and tau-mediated neurodegeneration independently of amyloid-β pathology. ApoE4 exerts a ‘toxic’ gain of function whereas the absence of ApoE is protective” David Holtzman, MD Washington University
Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.
University of South Florida researchers quantify Alzheimer’s and other neuro diseases at $800 billion per year
Read an overview of the substantial current and future economic impact of neurological disease, and an action plan for reducing this burden through neurological research and enhanced clinical management of neurological disorders in the US.
U.S. HHS released the National Plan to Address Alzheimer’s Disease: 2013 Update. The 2013 Update includes a new timeline for achieving its first goal – prevent and effectively treat Alzheimer’s disease by 2025 – and a review of progress over the past year.
The first-ever National Alzheimer’s Plan, initially released in May 2012, was mandated by the bipartisan National Alzheimer’s Project Act (P.L. 111-375), which Congress passed unanimously in 2010. The 2013 Update includes a new timeline for achieving its first goal – prevent and effectively treat Alzheimer’s disease by 2025 – and a review of progress over…
The UC Cures for Alzheimer’s Disease Initiative: A University of California-wide RFA now open for applications.
Sponsored by the UC Office of the President with a foundational grant of $4 million, the UC Cures initiative invited hundreds of laboratories throughout the 10-campus system to find new answers to Alzheimer’s disease and related disorders.
The NIA’s Bypass Budget Proposal for Fiscal Year 2018—Stopping Alzheimer’s Disease and Related Dementias: Advancing Our Nation’s Research Agenda is now available
At the direction of Congress, the National Institutes of Health (NIH) develops an annual professional judgment budget to estimate the funds needed to fully pursue scientific opportunities to meet the research goal of the Plan—to effectively treat and prevent Alzheimer’s and related dementias by 2025.
Presented, the Fiscal Year 2019 NIH Professional Judgment Budget for Alzheimer’s Disease and Related Dementias. Outlined at the July 28 meeting of the HHS Secretary’s Advisory Council on Alzheimer’s Research, Care, and Services.
Read “Rates of Cortical Atrophy in Adults 80 Years and Older With Superior vs Average Episodic Memory”
We now have more accurate ways of diagnosing Alzheimer’s and are moving closer to developing drugs to directly attack the disease. Much of this work is still in the early stages, but experts are growing more hopeful about dealing with the debilitating disease, which currently has no cure.
The FDA accepted Namzaric‘s New Drug Application (NDA) as a fixed-dose combination of memantine hydrochloride extended-release and donepezil hydrochloride tabilized on memantine hydrochloride and donepezil hydrochloride
“Namzaric combines, in one capsule, two complementary therapeutic agents which are often co-prescribed as approximately 70% of Namenda XR patients are also on AChEI therapy. Both Namenda XR and donepezil have proven efficacy and safety, for the treatment of moderate/severe Alzheimer’s disease.”
Read the exceptional compilation of AD-related data and statistics. Includes a Special Report on the Next Frontier of Alzheimer’s Research
A family with an astonishing rate of Alzheimer’s disease may harbor a powerful new gene.
Scientists report that raising levels of the life-extending protein klotho can protect against learning and memory deficits in a mouse model of Alzheimer’s disease.
Remarkably, this boost in cognition occurred despite the accumulation of Alzheimer-related toxins in the brain, such as amyloid-beta and tau.
Science of Translational Medicine: New in vivo data published on beta amyloid as a protectant against pathogens
A protein called Aβ is thought to cause neuronal death in Alzheimer’s disease (AD). Aβ forms insoluble aggregates in the brains of patients with AD, which are a hallmark of the disease. Aβ and its propensity for aggregation are widely viewed as intrinsically abnormal. However, in new work, Kumar et al. show that Aβ is…
These concepts were approved at the National Advisory Council on Aging (NACA) meeting on January 18, 2017. We have posted the approved concepts here to give interested researchers maximal lead time to plan projects.
Read the Alzheimer’s Forum analysis of the new AD-genetic risk score developed by Rahul Desikan (UCSF), Ole Andreassen (University of Oslo), Anders Dale (UCSD) and colleagues.
In lieu of a crystal ball that can foresee Alzheimer’s, scientists are trying to divine impending disease by looking deep into a person’s genome.